Home Regeneron Pharmaceuticals Given "Outperform" Rating at RBC Capital
 

Keywords :   


Regeneron Pharmaceuticals Given "Outperform" Rating at RBC Capital

2015-06-06 21:12:59| Biotech - Topix.net

REGN has been the subject of a number of other recent research reports. Analysts at Piper Jaffray reiterated a "neutral" rating and set a $484.00 price target on shares of Regeneron Pharmaceuticals in a research note on Thursday, May 21st.

Tags: rating capital pharmaceuticals rbc

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
05.07Samsung expects profits to jump by more than 1,400%
05.07Hurricane Beryl Graphics
05.07Hurricane Beryl Forecast Discussion Number 26
05.07Hurricane Beryl Wind Speed Probabilities Number 26
05.07Hurricane Beryl Forecast Advisory Number 26
05.07Hurricane Beryl Public Advisory Number 26
05.07Tropical Storm Aletta Graphics
05.07Tropical Storm Aletta Wind Speed Probabilities Number 3
More »